P1003 Effectiveness of Mirikizumab as induction therapy in ulcerative colitis -a prospective multicentre real-life study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
G Costantino, Anna Viola, A Iuculano, R Li Voti et autres
Abstract Background Mirikizumab (MIRI), a monoclonal IgG4 antibody against the p19 subunit of Interleukin 23 was recently licensed for the treatment of ulcerative colitis (UC). Most data come from the pivotal trials but real-life data are scant. The purpose of the present …
it, ar, es (code pays fourni par la source)